Merck & Co, INC Form 4 insider transactions

Director Peter C. Wendell reports acquisition of phantom stock units and disposition of common stock in Merck & Co., Inc.

Christine E. Seidman, a director at Merck & Co., Inc., acquired phantom stock units on March 28, 2024, according to a Form 4 filing with the SEC.

Director Thomas H. Glocer reports acquisition of phantom stock units and holdings in Merck & Co., Inc.

Director Mary Ellen Coe reports acquisition of phantom stock units convertible to common stock in a recent transaction.

Merck & Co., Inc. finalizes the acquisition of Harpoon Therapeutics through a merger, resulting in Merck becoming the direct beneficial owner of 100% of Harpoon's common stock.